Pictet - Biotech-P EUR

Performance (in EUR)

Past performance is no indication of current or future performance. These performance data do not take account of the commissions and costs incurred on the issue and redemption of units.

Performance

1 month 3.85%
Current year -9.35%
3 years p.a. 1.80%
5 years p.a. -1.06%
10 years p.a. -0.27%
Since inception p.a. n.a.

Rolling performance in %

Key figures

YTD 1 year 3 years 5 years 10 years
Performance -9.35% -17.22% 5.50% -5.21% -2.67%
Maximum profit on monthly basis 6.74% 6.74% 16.89% 16.89% 18.50%
Maximum loss on monthly basis -10.54% -10.54% -11.65% -17.41% -23.67%
Max drawdown -32.05% -36.31% -36.31% -37.42% -42.90%
Volatility 31.78% 28.67% 24.16% 25.28% 25.95%
Sharpe ratio -0.53 -0.68 -0.05 -0.08 -0.02
Maximum continuous profit in months 1 2 4 5 5
Maximum continuous loss in months 4 4 4 4 4
Positive months / profit duration in months 3 6 20 29 58
Negative months / loss duration in months 4 7 17 32 63

Master data

Fund name Pictet - Biotech-P EUR
Fund management company Pictet Asset Management (Europe) S.A.
Fund domicile Luxembourg
Inception date 14 June 2006
ISIN LU0255977455
Swiss security no. 2564944
Fund currency EUR
Appropriation of income accumulating
Issuing commission
Ongoing charges under PRIIP KID as at 07 February 2025 1.99%
End of financial year 30 September
Paying agent
Fund volume as at 30 May 2025 993.47 Mio. EUR
Net asset value (NAV) as at 15 July 2025 771.99 EUR

Portfolio structure

Top holdings of fund volume (in %)

arGEN-X NV 4.83%
Insmed 4.74%
Amgen 4.22%
Alnylam Pharma 3.90%
Gilead Sciences 3.67%
Regeneron Pharmaceuticals 3.13%
Merus B.V. 2.90%
TG Therapeutics Inc 2.88%
Blueprint Medicines Corp 2.78%
BridgeBio Pharma Inc 2.66%

Asset allocation

Currency

Countries

Sectors